Accounts Payable

3 Months Ended

Mar. 31, 2020

Accounts Payable

Accounts Payable

5.Accounts Payable

As of March 31, 2020, current liabilities included accounts payable of $0.8 million, comprised primarily of amounts owed for external research expenses related to manufacturing costs of $0.3 million, preclinical expenses of $0.3 million, legal and patent fees of $0.1 million and amounts owed to the Company's clinical research organization for its clinical trials for prexigebersen in AML and BP1002 in lymphoma of $0.1 million. As of December 31, 2019, current liabilities included accounts payable of $0.5 million, comprised primarily of amounts owed for external research expenses related to manufacturing costs of $0.3 million and legal and patent fees of $0.2 million.